Myelodysplastic Syndromes

Clinical pathways in MDS treatment are explored by Amer Zeidan, MBBS, MHS, and Jay Weaver, PharmD, MPH.

Key considerations for appropriate MDS treatment selection are discussed by expert panelists.

Salman Fazal, MD, shares opinions regarding the role of hypomethylating agents (HMAs) in treatment for patients with MDS.

Experts discuss the impact of supportive care in the MDS treatment landscape.

Drs Zeidan and Fazal share their opinions on setting appropriate goals for treatment of patients with MDS.

Jay Weaver, MD, highlights MDS treatment strategies driven by optimal health resource management.

Expert panelists explore challenges impacting care access for patients with MDS.

Amer Zeidan, MBBS, MHS, navigates prognostic models utilized for considerations surrounding patients with lower-risk and higher-risk MDS.

Ryan Haumschild, PharmD, MS, MBA, leads expert panelists in a conversation exploring the prevalence and clinical burden impact of MDS.

Key opinion leaders discuss the impact MDS can have on the quality of life for patients compared with other hematologic disease states.

A panel of experts open a discussion on the expanding awareness of myelodysplastic syndromes (MDS).

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, discussed current knowledge on the molecular profile of myelodysplastic syndromes (MDS) and potential use of precision medicine.

Elli Papaemmanuil, PhD, assistant professor in computational oncology, Memorial Sloan Kettering Cancer Center, spoke on current methods of classification and stratification for myelodysplastic syndromes (MDS) and the applicability of a novel scoring system, presented during her plenary session at EHA2022, that aims to improve and refine MDS risk estimation.

Panelists look toward the future management of myelodysplastic syndromes with respect to novel agents and treatment pathways.

Experts reflect on interchangeability between oral and intravenous therapy in patients with higher-risk myelodysplastic syndromes.

Practical considerations for managing patient adherence on an oral therapy for higher-risk myelodysplastic syndromes.

Shared insight on the historical and current use of hypomethylating agents in patients with myelodysplastic syndromes.

Perspectives on the use of oral HMA therapy in higher-risk myelodysplastic syndromes, and how this has improved patient care.

Expert panelists discuss when it’s appropriate to consider or continue ESA therapy or blood transfusions in patients with MDS.

Panelists share insight on therapeutic goals when treating patients with myelodysplastic syndromes.

A brief review of disease and patient factors that influence the selection of therapy for myelodysplastic syndromes.

Reflections on the historical use of ESAs and blood transfusions to treat patients with myelodysplastic syndromes.

Experts consider shortcomings in the identification and management of myelodysplastic syndromes.

Practical perspectives on how to communicate MDS subclassifications with affected patients and caregivers.

Expert perspectives on the changes in MDS subclassifications as understandings of the disease have evolved.

Shared insight on how to best educate patients and caregivers on the broad nature of myelodysplastic syndromes.

A panel of experts discuss the complex nature of myelodysplastic syndromes and concurrent subclassifications.

A flow cytometric score developed in 2012, which uses 4 parameters to distinguish low-grade myelodysplastic syndromes (MDS) from nonclonal cytopenias, is simple and practical for screening patients with MDS, according to research published in the American Journal of Translational Research.

New research underscores the substantial economic burden associated with early discontinuation of guideline-recommended hypomethylating agent (HMA) therapy among patients with refractory anemia with excess blasts, a diagnosis that substantially overlaps with higher-risk myelodysplastic syndrome (MDS).

A recent study evaluated the content validity of patient-reported outcome instruments used in low-risk myelodysplastic syndrome (MDS).